Drug Trial Radar · NCT01027949
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
Last checked: Nov 19, 2026Latest source record: May 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
894
Actual
Start
Jan 16, 2007
Primary completion
Feb 12, 2020
Study completion Feb 12, 2020
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308. The study assessed the long term safety of oral treprostinil and the effect of continued treatment with oral treprostinil on exercise capacity after 1 year of treatment.
Conditions
- Pulmonary Arterial Hypertension
Interventions
Oral TreprostinilDrug
Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Exercise Capacity at Month 12Time frame: From First Visit (Visit 1) to Month 12
Locations
134 sites in 20 countries. Site status is shown where the registry gives one.
The Kirklin Clinic
Birmingham, Alabama
Arizona Pulmonary Specialists, Ltd.
Phoenix, Arizona
Mayo Clinic Phoenix
Phoenix, Arizona
St. Joseph's Hospital and Medical Center
Phoenix, Arizona
University Medical Center
Tucson, Arizona
University of Arizona Clinical and Translational Science (CATS) Research Center
Tucson, Arizona
University of California, San Francisco-Fresno
Fresno, California
West Los Angeles VA Healthcare Center
Los Angeles, California
David Geffen School of Medicine at UCLA
Los Angeles, California
UC Davis Medical Center
Sacramento, California
UCSD Medical Center
San Diego, California
University of California San Francisco Medical Center
San Francisco, California
Stanford University, Pulmonary and Critical Care Medicine
Stanford, California
Harbor-UCLA Medical Center
Torrance, California
The Children's Hospital
Aurora, Colorado
University of Colorado Health Science Center
Aurora, Colorado
University of Florida College of Medicine Jacksonville
Jacksonville, Florida
Cleveland Clinic Florida
Weston, Florida
The Emory Clinic
Atlanta, Georgia
The University of Chicago Hospitals
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Kentuckiana Pulmonary Associates
Louisville, Kentucky
Alexandria Cardiology Clinic
Alexandria, Louisiana
Maine Medical Center
Portland, Maine
University of Maryland Medical Center
Baltimore, Maryland
Johns Hopkins Outpatient Center
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Brigham and Woman's Hospital
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Newark Beth Israel Medical Center
Newark, New Jersey
Winthrop University Hospital
Mineola, New York
Columbia University Medical Center
New York, New York
Mary Parkes Center
Rochester, New York
University of North Carolina Hospitals
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
Showing 40 of 134 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.